Abstract
Six healthy male volunteers were given 5, 20, and 50 mg of oral prednisone and 5, 20, and 40 mg doses of intravenous prednisolone. Plasma and urine concentrations of prednisone and prednisolone were determined by HPLC, and the binding of prednisolone to plasma proteins was measured by radioisotopic and equilibrium dialysis techniques. The pharmacokinetics of both oral prednisone and intravenous prednisolone were dose-dependent. The mean oral dose plasma clearances of prednisone ranged from 572 ml/min/ 1.73 m 2 for the 5mg dose to 2271 ml/min/1.73 m 2 for the 50 mg dose. Changes in prednisone half-life were insignificant, but increases in the half-life of its metabolite were dose-dependent. The systemic plasma clearance of i.v. prednisolone was dose-dependent and increased from 111 to 194 ml/min/1.73 m 2 over the 5 to 40 mg i.v. dosage range. The steady-state volume of distribution also increased, but little change in mean transit time and half-life was found. The binding of prednisolone to plasma proteins was markedly concentration-dependent, and a two compartment, nonlinear equation was used to characterize the effective binding of prednisolone to transcortin and albumin. The apparent pharmacokinetic parameters of protein-free and transcortin-free prednisolone were relatively constant with dose. The interconversion of prednisone and prednisolone varied with time and dose, although prednisolone concentrations dominated by 4-to 10-fold over prednisone. In urine, 2–5% of either administered drug was excreted as prednisone and 11–24% as prednisolone. The apparent renal clearances of both steroids were also nonlinear and unrelated to protein binding. These studies indicate that the pharmacokinetics of prednisone and prednisolone are dose-dependent and that protein binding does not fully explain their apparent nonlinear distribution and disposition.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
H. G. Morris. Pharmacology and corticosteroids in asthma. In E. Middleton Jr., C. Reed, and E. Ellis (eds.),Allergy Principles and Practice, C. V. Mosby, St. Louis, 1978, pp. 464–480.
P. L. Ballard. Delivery and transport of glucocorticoids to target cells. In J. D. Baxter and G. G. Rousseau (eds.),Glucocorticoid Hormone Action, Monogr. Endocrinol, Springer, Heidelberg, 1979, pp. 25–48.
G. P. Lewis, W. J. Jusko, C. W. Burke, and L. Graves. Prednisone side-effects and serum protein levels,Lancet, 778–781 (Oct. 9, 1971).
A. W. Meikle, J. A. Weed, and F. H. Tyler. Kinetics and interconversion of prednisolone and prednisone studied with new radioimmunoassays,J. Clin. Endocrinol. Metab. 41:717–721 (1975).
M. E. Pickup, J. R. Lose, P. A. Leatham, V. M. Rhind, V. Wright, and W. W. Downie. Dose dependent pharmacokinetics of prednisolone,eur. J. Clin. Pharmacol. 12:213–219 (1977).
J. Q. Rose, A. M. Yurchak, and W. J. Jusko. Dose dependent pharmacokinetics of prednisolone in man. InAbstracts of the 7th International Congress of Pharmacology, Paris, July 16–21. Pergamon Press, Oxford, 1978.
J. C. K. Loo, I. J. McGilveray, N. Jordan, J. Moffat, and R. Brien. Dose dependent pharmacokinetics of prednisone and prednisolone in man,J. Pharm. Pharmacol. 30:736 (1978).
A. Tanner, F. Bochner, J. Caffin, J. Halliday, and L. Powell. Dose dependent prednisolone kinetics,Clin. Pharmacol. Ther. 25:571–578 (1979).
J. Q. Rose, A. M. Yurchak, and W. J. Jusko. Bioavailability of two 50 mg prednisone formulations in man. In Abstracts of A.Ph.A. Academy of Pharmaceutical Sciences, Montreal, May 13–18,1978.
P. S. Chen, I. H. Mills, and F. C. Bartter. Ultrafiltration studies of steroid-protein binding,J. Endocrinol. 23:129–137 (1961).
J. Q. Rose and W. J. Jusko. Corticosteroid analysis in biological fluids by high-performance liquid chromatography.J. Chromatogr. 162:273–280 (1979).
Packard Instrument Manual #2136 for Model 3255 Tri-Carb Liquid Scintillation Spectrometer System: Sample Channels Ratio, pp. 3–9.
M. Gibaldi and D. Perrier: Trapezoidal rule. In J. Swarbrick (ed.)Pharmacokinetics, Marcel Dekker, New York, 1975, pp. 293–296.
C. M. Metzler. NONLIN, a computer program for nonlinear least-squares regression. The Upjohn Company, Kalamazoo, Mich., 1974.
K. Yamaoka, T. Nakagawa, and T. Uno. Statistical moments in pharmacokinetics,J. Pharmacokin. Biopharm. 6:547–557 (1978).
N. A. Lassen and W. Perl.Tracer Kinetic Methods in Medical Physiology. Raven Press, New York, 1979, pp. 76–80.
J. Q. Rose, A. M. Yurchak, W. J. Jusko, and D. Powell. Bioavailability and disposition of prednisone and prednisolone from prednisone tablets,Biopharm. Drug. Disp. 1:247–258 (1980).
T. G. Muldoon and V. Westphal. Steroid-protein interactions XV. Isolation and characterization of corticosteroid binding globulin from human plasma.J. Biol. Chem. 242:5636–5643 (1967).
J. F. Tait and S. Burstein. In vivo studies of steroid dynamics. In G. Pincus, K. V. Thimann, and E. B. Astwood (eds.)The Hormones, Academic Press, New York, 1964, pp. 441–557.
P. DeMoor, R. Deckx, and O. Steeno. Influence of various steroids on the specific binding of cortisol.J. Endocrinol. 27:355–356.
R. D. Zipser, P. F. Speckart, P. K. Zia, W. A. Edmiston, F. Y. K. Lau, and R. Horton. The effect of ACTH and cortisol on aldosterone and cortisol clearance and distribution in plasma and whole blood,J. Clin. Endocrinol. Metab. 43:1101–1109 (1976).
W. A. Hsueh, A. Paz-Guevara, and T. Bledsoe. Studies comparing the metabolic clearance rate of 11β,17,21-trihydroxypregn-l,4-diene-3,2D-dione(prednisolone) after oral 17,21-dihydroxypregn-1,4-diene-3 11,20-trione and intravenous prednisolone.J. Clin. Endocrinol. Metab. 48:748–752 (1979).
M. L. Rocci, S. J. Szefler, M. Acara, and W. J. Jusko. Prednisolone and prednisone metabolism and excretion in the isolated perfused rat kidney.Pharmacologist 21:184 (1979).
M. L. Rocci and W. J. Jusko. Prednisolone serum protein binding in four species.J. Pharm. Sci. 69:977–978 (1980).
J. Q. Rose, J. A. Nickelsen, E. Middleton, Jr., A. M. Yurchak, B. Park, and W. J. Jusko. Prednisolone disposition in steroid dependent asthmatics.J. Allerg. Clin. Immunol (1981).
G. J. Pepe, E. D. Albrecht, and J. D. Townsley. Serum cortisol levels affect the metabolic clearance rate of progesterone in female baboons.Steroids 30:561–568.
W. J. Jusko and M. Gretch. Plasma and tissue binding of drugs in pharmacokinetics.Drug Metab. Rev. 5:43–140 (1976).
P. G. Zager, W. J. Burtis, J. A. Luetscher, A. J. Dowdy, and S. Sood. Increased plasma protein binding and lower metabolic clearance rate of aldosterone in plasma of low cortisol concentration.J. Clin. Endocrinol. Metab. 42:207–214 (1976).
A. Vermuelen and S. Ando. Metabolic clearance rate and interconversion of androgens and the influence of the free androgen fraction.J. Clin. Endocrinol. Metab. 48:320–326 (1979).
C. A. Nugent, K. Eik-nes, and F. H. Tyler. A comparative study of the metabolism of hydrocortisone and prednisolone,J. Clin. Endocrinol. Metab. 19:526–534 (1959).
S. M. El Dareer, R. F. Struck, V. M. White, L. B. Mellett, and D. L. Hill. Distribution and metabolism of prednisone in mice, dogs and monkeys.Cancer Treat. Rep. 61:1279–1289 (1977).
J. Hartiala. Steroid metabolism in adult lung.Agents and Actions 6:522–526 (1976).
C. Baylis and B. M. Brenner. Mechanism of the glucocorticoid-induced increase in glomerular filtration rate.Am. J. Physiol. 234:F166-F170 (1978).
A. Breckenridge, C. W. Burke, D. S. Davies, and M. L. E. Orme. Immediate decrease by hydrocortisone of the plasma half-life of antipyrine.Br. J. Pharmacol. 47:434–436 (1973).
J. Aarbakke, M. R. Bending, and D. S. Davies. Increased oxidation of phenylbutazone during hydrocortisone infusion in man.Br. J. Clin. Pharmacol. 4:621–622 (1977).
C. A. Shively, C. L. Gagbardi, R. D. Hartshorn, and E. Vessell. Failure of hydrocortisone to alter acutely antipyrine disposition.Clin. Pharmacol. Ther. 23:408–413 (1978).
P. Saenger, A. B. Rifkind, and J. Pareira. Effect of glucocorticoids and ACTH on antipyridine clearance in children.Clin. Pharmacol. Ther. 23:692–696 (1978).
W. R. Beisel, J. J. Cos, R. Horton, P. Y. Chao, and P. H. Forsham. Physiology of urinary cortisol excretion.J. Clin. Endocrinol. 24:887–893 (1964).
J. O. Davies and D. S. Howell. Comparative effect of ACTH, cortisone and DOCA on renal function, electrolyte excretion and water exchange in normal dogs.Endocrinology 52:245–255 (1953).
L. deBermudez and J. P. Hayslett. Effect of methylprednisolone on renal function and the zonal distribution of blood flow in the rat.Circ. Res. 31:44–52 (1972).
M. F. Levitt and M. E. Bader. Effect of cortisone and ACTH on fluid and electrolyte distribution in man.Am. J. Med. 11:715–723 (1953).
M. M. Pechet, B. Bowers, and F. C. Bartter. Metabolic studies with a new series of 1,4-diene steroids: II. Effects in normal subjects of prednisone, prednisolone and9α- fluoro-prednisolone.J. Clin. Invest. 38:691–701 (1959).
D. Jenkins and J. E. Schemmel. Metabolic effects of 6-methylprednisolone.Metabolism 7:416–424 (1958).
W. R. Slaunwhite, Jr., G. N. Lockie, N. Back, and A. A. Sandberg. Inactivity in vivo of transcortin-bound cortisoi.Science 135:1062 (1962).
J. Y. F. Paterson and F. A. Harrison. The splanchnic and hepatic uptake of cortisoi in conscious and anaesthetized sheep.J. Endocrinol. 55:335–350 (1972).
B. E. P. Murphy. The influence of serum proteins on the metabolism of cortisoi by the human placenta.J. Steroid Biochem. 10:387–392 (1979).
N. Keller, V. I. Richardson, and F. E. Yates. Protein binding and the biological activity of corticosteroids: In vivo induction of hepatic and pancreatic alanine aminotransferases by corticosteroids in normal and estrogen-treated rats.J. Endocrinol. 84:49–62 (1969).
W. M. Pardridge and L. J. Mietus. Transport of protein-bound steroid hormones into liver in vivo.Am. J. Physiol. 237:E367-E372 (1979).
J. Q. Rose, J. A. Nickelsen, and W. J. Jusko. Prednisolone pharmacokinetics in relation to dose.J. Pediatr. 94:1014 (1979).
W. J. Jusko, J. R. Koup, and G. Alvan. Nonlinear assessment of phenytoin bioavailability.J. Pharmacokin. Biopharm. 4:327–336 (1976).
T. J. Sullivan, M. R. Hallmark, E. Sakmar, D. J. Weidler, R. H. Earhart, and J. G. Wagner. Comparative bioavailability: eight commercial prednisone tablets.J. Pharmacokin. Biopharm. 4:157–172 (1976).
Author information
Authors and Affiliations
Additional information
This work was supported in part by Grant 24211 from the National Institutes of General Medical Sciences, National Institutes of Health.
Rights and permissions
About this article
Cite this article
Rose, J.Q., Yurchak, A.M. & Jusko, W.J. Dose dependent pharmacokinetics of prednisone and prednisolone in man. Journal of Pharmacokinetics and Biopharmaceutics 9, 389–417 (1981). https://doi.org/10.1007/BF01060885
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01060885